PhaseBio Pharmaceuticals, Inc.
PHAS · NASDAQ
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | -$0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -96.6% | -86.4% | 253.4% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 0.1% | 100% | 100% |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 15,350.2% | -30,191.3% | -1,609.4% | -2,966.6% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,210.1% | -30,801.6% | -1,662.3% | -3,569.8% |
| EPS Diluted | -0.005 | -3.39 | -1.43 | -4.49 |
| % Growth | 99.9% | -137.1% | 68.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |